Background: The Harris hawk is a bird of prey susceptible to traumatic injuries because it is useful for several purposes such as conservancy, biological control and falconry. Once received in rehabilitation centres or specialized clinics, it is necessary to provide proper analgesia.
Objectives: The aim of this study is to demonstrate the analgesic efficacy of tramadol in Harris hawks (PISADOL 50 PiSA Agropecuaria, S.A. de C.V. Calle 1 Norte, Manzana 2-25 Parque Industrial Tula Atitalaquia, Hgo, México), by the assessment of nociceptive threshold.
Methods: A total of 24 adult Harris hawks were selected from a rehabilitation centre. The birds were randomly divided into four groups: control (saline solution), 5.0, 15.0 and 30.0 mg/kg of intramuscular tramadol. Nociception was produced with electrical stimuli of 9 V, applied in propatagial skin at 1, 5, 10, 20, 30, 45, 60, 90, 120, 180, 240, 300 and 360 min, assessing the nociceptive threshold and sedative effects produced by each treatment.
Results: No difference was observed between control and tramadol group 5 mg/kg. At 15 mg/kg, the pain threshold increased from 20 to 240 min, with minimal sedative effects. At 30 mg/kg, there was a marked increase in pain threshold from 10 to 300 min, and sedative effects like wing and head drooping for a period of 90 min.
Conclusions: Tramadol can be an analgesic alternative for Harris's hawks, as it decreases the response to painful stimuli in this species when administered by intramuscular route.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650257 | PMC |
http://dx.doi.org/10.1002/vms3.1304 | DOI Listing |
Pediatr Crit Care Med
January 2025
Perioperative & Critical Care-Center for Outcomes Research and Evaluation (PC-CORE), Boston Children's Hospital, Boston, MA.
Objectives: Sedation assessment and goal setting using a validated assessment tool are key components of the ICU Liberation bundle. Appropriate integration of these bundle elements into daily practice remains challenging. Understanding barriers is an important step toward implementation of these best practice bundle elements.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden; Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.
Background: A significant number of individuals with Alzheimer's disease (AD) reside independently in their homes, yet there is limited understanding of whether they receive comparable diagnostic and treatment standards for AD compared to their cohabiting counterparts. The prevalence of dementia is rising, particularly among the elderly, with approximately 150,000 individuals affected by dementia in Sweden, two-thirds of whom have AD. The national quality registry SveDem (Swedish registry for cognitive (dementia disorders) was established to promote consistent and high-quality dementia care across the country.
View Article and Find Full Text PDFBackground: Sleep disturbances are prevalent in Alzheimer's disease (AD), impacting cognition and quality of life. Trials have also shown increased subjective sleepiness with melatonin doses compared to placebo. High melatonin doses may increase drowsiness, headache, and dizziness, as indicated by a systematic review.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
BioXcel Therapeutics, New Haven, CT, USA.
Background: BXCL501, a sublingual film formulation of dexmedetomidine, a highly selective α2 adrenoceptor agonist, is currently being studied for the acute treatment of agitation associated with dementia.
Method: This was a Phase 1b/2 study assessing efficacy and tolerability of BXCL501 for treatment of acute agitation associated with dementia. Subjects were randomized to active treatment with BXCL501 (30, 40, or 60µg) or placebo.
Crit Care Resusc
December 2024
Department of Intensive Care, Austin Hospital, Heidelberg, Victoria, Australia.
Objective: To assess current evidence regarding guanfacine use in hospitalized patients with delirium.
Introduction: Delirium is a common and important complication of critical illness. Central alpha-2 agonists are often used for symptomatic management.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!